Collocating Novel Targets for Tuberculosis (TB) Drug Discovery

Author(s): Karan Gandhi, Mehul Patel*

Journal Name: Current Drug Discovery Technologies

Volume 18 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Mycobacterium tuberculosis, being a resistive species is an incessant threat to the world population for the treatment of Tuberculosis (TB). An advanced genetic or a molecular level approach is mandatory for both diagnosis and therapy as the prevalence of multi drug-resistant (MDR) and extensively drug- resistant (XDR) TB.

Methods: A literature review was conducted, focusing essentially on the development of biomarkers and targets to extrapolate the Tuberculosis Drug Discovery process.

Results and Discussion: In this article, we have discussed several substantial targets and genetic mutations occurring in a diseased or treatment condition of TB patients. It includes expressions in Bhlhe40, natural resistance associated macrophage protein 1 (NRAMP1) and vitamin D receptor (VDR) with its mechanistic actions that have made a significant impact on TB. Moreover, recently identified compounds; imidazopyridine amine derivative (Q203), biphenyl amide derivative (DG70), azetidine, thioquinazole, tetrahydroindazole and 2- mercapto- quinazoline scaffolds for several targets such as adenosine triphosphate (ATP), amino acid and fatty acid have been briefed for their confirmed hits and therapeutic activity.

Keywords: Adenosine triphosphate (ATP), amino acid, fatty acid, interferon- γ, Interleukin-10, natural resistance associated macrophage protein 1 (NRAMP1).

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 2
Year: 2021
Published on: 19 February, 2021
Page: [307 - 316]
Pages: 10
DOI: 10.2174/1570163817666200121143036
Price: $65

Article Metrics

PDF: 21